Diverticular disease (DD) is a common gastrointestinal condition. Patients with DD experience a huge variety of chronic nonspecific symptoms, including abdominal pain, bloating, and altered bowel habits.
They are also at risk of complications such as acute diverticulitis, abscess formation, hemorrhage, and perforation.
Intestinal dysbiosis and chronic inflammation have recently been recognized as potential key factors contributing to disease progression.
Probiotics, due to their ability to modify colonic microbiota balance and to their immunomodulatory effects, could present a promising treatment option for patients with DD.
Lactobacillus paracasei CNCM I 1572 (LCDG) is a probiotic strain with the capacity to rebalance gut microbiota and to decrease intestinal inflammation.
This review summarizes the available clinical data on the use of LCDG in subjects with colonic DD.
Lactobacillus paracasei CNCM I-1572; probiotics; acute diverticulitis; diverticular disease; symptomatic uncomplicated diverticular disease
Elisabetta Bretto, Ferdinando D’Amico, Walter Fiore, Antonio Tursi and Silvio Danese.
Part of the information contained in this website is exclusively addressed to healthcare professionals. Please confirm that you are a healthcare professional. Are you a healthcare professional?
This website contains links/references to third-party websites. By such links, SOFAR does not provide any guarantee nor gives its approval to their contents and quality. SOFAR does not have and does not accept any responsibility for the contents or the availability of such websites; SOFAR does not accept any liability for damage or injury resulting from the use of such contents, of whatever form. Users access such websites at their own risk. The information contained in this website is for information purposes only and not for diagnostic or therapeutic purposes. Thus, it does not substitute in any way medical and /or expert or other healthcare professionals or specialists ‘advice.